immatics biotechnologies GmbH

Development of peptide-based cancer immunotherapeutics

immatics was created in 2000 as a spin-off from the Institute of Immunology at the University of Tuebingen.

Harpreet Singh, Ph.D., Managing Director, CSO
Niels Emmerich, Ph.D., Managing Director, COO
Jürgen Frisch, M.D., Managing Director, CMO

Thomas Widman, M.D., Chairman
Friedrich von Bohlen und Halbach, Ph.D.
Prof. Erich Schlick, M.D.
Sebastian Meier-Ewert, Ph.D.
Klaus Stoeckemann, Ph.D.
Christof Hettich

Hans-Georg Rammensee, Ph.D., Prof.
Christoph Huber, Ph.D., Prof.
Cornelius Melief, M.D., Prof.
Craig Slingluff Jr., M.D., Prof.
Pedro Romero, M.D., Prof.

Paul-Ehrlich-Str. 15
72076 Tübingen
Germany
Phone: +49-7071-565125-0
Fax: +49-7071-565125-99

immatics is an independent biopharmaceutical company that focuses on the development of new immunotherapeutic substances for cancer therapy. The product candidates from immatics are based upon tumor-associated peptides (TUMAPs) that specifically stimulate the immune system against cancer cells. In November 2005 – and thus only 22 months after the conclusion of its first round of funding totaling €14 million – the company launched an international clinical study on its product candidate IMA901 for combating renal cell cancer. Further product candidates, also consisting of peptide-based immunotherapeutic substances for cancer therapy, are presently undergoing preclinical development and will serve as the basis for a rapidly expanding product pipeline.

Formed in the year 2000 as a spin-off from the Institute of Immunology at the University of Tübingen, immatics today employs a staff of more than 35 people. The members of immatics’ Supervisory Board include the head of the institute, Hans-Georg Rammensee, as well as Actelion co-founder Thomas Widmann, the former global head of regulatory affairs at Bayer AG, Ulrich Granzer, and GPC Biotech CSO Sebastian Meier-Ewert.

The cancer vaccine IMA901 for the treatment of renal cell carcinoma (RCC) successfully completed the drug discovery and pre-clinical phase. The phase I clinical trial has begun in 2005.
immatics aims to have 2 products in phase II, 2 in phase I clinical trial and to complete pre-clinical phases of 2 products by 2008.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.